Impact of psychiatric disorders on the hemodynamic and quality of life outcome of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: a retrospective study.
Balloon pulmonary angioplasty
Chronic thromboembolic pulmonary hypertension
Psychiatric disorder
Quality of life
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
11 Nov 2023
11 Nov 2023
Historique:
received:
15
07
2023
accepted:
25
10
2023
medline:
13
11
2023
pubmed:
12
11
2023
entrez:
11
11
2023
Statut:
epublish
Résumé
Balloon pulmonary angioplasty (BPA) has beneficial effects on pulmonary hemodynamics, exercise capacity, and quality of life (QOL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Recently, emerging evidence suggests a relationship between CTEPH and psychiatric disorders (PD). However, data on the clinical efficacy of BPA in CTEPH patients with PD are lacking. We retrospectively analyzed 75 patients with inoperable/residual CTEPH who underwent BPA and right-sided heart catheterization before the initial BPA and within 1 year after the last procedure. QOL was evaluated using the European Quality of Life Five Dimension (EQ-5D) scale in 27 patients before and after BPA sessions. Baseline and post-procedural hemodynamic, functional, and QOL parameters were compared between the patients with and without PD. Among the 75 participants, 22 (29.3%) patients were categorized in the PD group. Although PD group had a similar mean pulmonary artery pressure level compared with non-PD group (40 ± 7 vs. 41 ± 9 mmHg, p = 0.477), they tended to have unfavorable QOL status (0.63 ± 0.22 vs. 0.77 ± 0.19, p = 0.102). BPA significantly improved pulmonary hemodynamics, laboratory parameters and exercise tolerance in both groups. BPA also significantly improved EQ-5D scores in the non-PD group (from 0.77 ± 0.19 to 0.88 ± 0.13, p < 0.001), but the scores remained unchanged in the PD group (from 0.63 ± 0.22 to 0.67 ± 0.22, p = 0.770). During the long-term period [1,848 (1,055-2,565) days], both groups experienced similar mortality rates (PD 4.6% vs. non-PD 5.7%, p = 1.000). BPA improved hemodynamic and functional parameters irrespective of PD, but its effect on QOL was limited in patients with PD.
Sections du résumé
BACKGROUND
BACKGROUND
Balloon pulmonary angioplasty (BPA) has beneficial effects on pulmonary hemodynamics, exercise capacity, and quality of life (QOL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Recently, emerging evidence suggests a relationship between CTEPH and psychiatric disorders (PD). However, data on the clinical efficacy of BPA in CTEPH patients with PD are lacking.
METHODS
METHODS
We retrospectively analyzed 75 patients with inoperable/residual CTEPH who underwent BPA and right-sided heart catheterization before the initial BPA and within 1 year after the last procedure. QOL was evaluated using the European Quality of Life Five Dimension (EQ-5D) scale in 27 patients before and after BPA sessions. Baseline and post-procedural hemodynamic, functional, and QOL parameters were compared between the patients with and without PD.
RESULTS
RESULTS
Among the 75 participants, 22 (29.3%) patients were categorized in the PD group. Although PD group had a similar mean pulmonary artery pressure level compared with non-PD group (40 ± 7 vs. 41 ± 9 mmHg, p = 0.477), they tended to have unfavorable QOL status (0.63 ± 0.22 vs. 0.77 ± 0.19, p = 0.102). BPA significantly improved pulmonary hemodynamics, laboratory parameters and exercise tolerance in both groups. BPA also significantly improved EQ-5D scores in the non-PD group (from 0.77 ± 0.19 to 0.88 ± 0.13, p < 0.001), but the scores remained unchanged in the PD group (from 0.63 ± 0.22 to 0.67 ± 0.22, p = 0.770). During the long-term period [1,848 (1,055-2,565) days], both groups experienced similar mortality rates (PD 4.6% vs. non-PD 5.7%, p = 1.000).
CONCLUSIONS
CONCLUSIONS
BPA improved hemodynamic and functional parameters irrespective of PD, but its effect on QOL was limited in patients with PD.
Identifiants
pubmed: 37951929
doi: 10.1186/s12931-023-02579-z
pii: 10.1186/s12931-023-02579-z
pmc: PMC10638767
doi:
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
274Informations de copyright
© 2023. The Author(s).
Références
J Thromb Haemost. 2023 Aug;21(8):2151-2162
pubmed: 37044277
Front Psychiatry. 2022 Mar 02;13:821466
pubmed: 35308878
Circ J. 2017 Mar 24;81(4):552-557
pubmed: 28154291
Epidemiol Psychiatr Sci. 2016 Jun;25(3):217-29
pubmed: 26148821
J Cardiol. 2020 Feb;75(2):182-188
pubmed: 31427133
Circ Cardiovasc Interv. 2012 Dec;5(6):748-55
pubmed: 23192917
Pharmacoeconomics. 2018 Jun;36(6):675-697
pubmed: 29470821
Schizophr Res. 2015 Mar;162(1-3):248-52
pubmed: 25623600
J Cardiol. 2020 Aug;76(2):205-210
pubmed: 32402668
Circulation. 2011 Nov 1;124(18):1973-81
pubmed: 21969018
PLoS One. 2021 Jul 23;16(7):e0255180
pubmed: 34297758
Eur Heart J. 2017 Nov 07;38(42):3152-3159
pubmed: 29029023
Front Psychiatry. 2021 May 31;12:667602
pubmed: 34135787
Circ Cardiovasc Qual Outcomes. 2017 Nov;10(11):
pubmed: 29101270
Int J Cardiol. 2016 Mar 15;207:363-4
pubmed: 26820368
Lancet Psychiatry. 2018 Jun;5(6):477-485
pubmed: 29731412
Circulation. 2016 Dec 13;134(24):2030-2032
pubmed: 27956405
Respir Res. 2013 Oct 09;14:104
pubmed: 24107187
Psychiatry Clin Neurosci. 2012 Dec;66(7):541-52
pubmed: 23252920
Open Heart. 2020 Feb 27;7(1):e001144
pubmed: 32180986
Lancet Psychiatry. 2022 Feb;9(2):137-150
pubmed: 35026139
Circ Cardiovasc Interv. 2012 Dec;5(6):756-62
pubmed: 23132237
Health Qual Life Outcomes. 2010 May 05;8:47
pubmed: 20444251
Chest. 2001 Mar;119(3):818-23
pubmed: 11243963
Pulm Circ. 2019 Jan-Mar;9(1):2045894019836420
pubmed: 30777485
Biol Psychiatry. 1990 Apr 15;27(8):863-70
pubmed: 1970485
Circulation. 2001 Jan 2;103(1):10-3
pubmed: 11136677
J Am Coll Cardiol. 2020 Nov 3;76(18):2155-2169
pubmed: 33121723
BMJ. 2010 Sep 21;341:c4245
pubmed: 20858909
Eur Heart J. 2022 Oct 11;43(38):3618-3731
pubmed: 36017548
EuroIntervention. 2018 Apr 20;13(17):2060-2068
pubmed: 28804055
J Thromb Haemost. 2016 Jan;14(1):121-8
pubmed: 26509468
Pharmacopsychiatry. 2011 Jul;44(5):183-8
pubmed: 21739416